Analyst Backing Propels Zealand Pharma Shares Ahead of ADA 2026 Obesity Data
Zealand Pharma A/S shares rose more than 7% on Thursday ahead of scheduled obesity pipeline presentations at the American Diabetes Association’s 2026 Scientific Sessions. Jefferies kept a buy rating and DKK505 price target, while Deutsche Bank retained a hold rating and raised its target to DKK300. The company will present Phase 2 results for petre…